Evidence map›Paper›PMID 39663357›Full record

ArticleJournal of human genetics2025

Cancer and disease profiles for PTEN pathogenic variants in Japanese population.

Yuki Kanazashi, Yoshiaki Usui, Yusuke Iwasaki, Shota Sasagawa, Mikiko Endo, Mitsuyo Yamaguchi, Todd A Johnson, Kazuhiro Maejima, Kouya Shiraishi, Takashi Kohno and 8 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of human genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Yuki KanazashiLaboratory for Cancer Genomics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
Yoshiaki UsuiLaboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.ORCID http://orcid.org/0000-0001-6180-0704
Yusuke IwasakiLaboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
Shota SasagawaLaboratory for Cancer Genomics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
Mikiko EndoLaboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
Mitsuyo YamaguchiLaboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
Todd A JohnsonLaboratory for Cancer Genomics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
Kazuhiro MaejimaLaboratory for Cancer Genomics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
Kouya ShiraishiDivision of Genome Biology, National Cancer Center Research Institute, Tokyo, Japan.ORCID http://orcid.org/0000-0002-5821-7400
Takashi KohnoDivision of Genome Biology, National Cancer Center Research Institute, Tokyo, Japan.ORCID http://orcid.org/0000-0002-5371-706X
Teruhiko YoshidaDepartment of Genetic Medicine and Services, National Cancer Center Hospital, Tokyo, Japan.
Kokichi SuganoDepartment of Genetic Medicine and Services, National Cancer Center Hospital, Tokyo, Japan.
Yoshinori MurakamiDapartment of Molecular Biology, Institute for Advanced Medical Sciences, Nippon Medical School, Tokyo, Japan.
Yoichiro KamataniLaboratory of Complex Trail Genomics, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.ORCID http://orcid.org/0000-0001-8748-5597
Naomichi MatsumotoDepartment of Human Genetics, Yokohama City University Graduate School of Medicine, Yokohama, Japan.ORCID http://orcid.org/0000-0001-9846-6500
Koichi MatsudaLaboratory of Clinical Genome Sequencing, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.
Yukihide MomozawaDepartment of Human Genetics, Yokohama City University Graduate School of Medicine, Yokohama, Japan. momozawa@riken.jp.ORCID http://orcid.org/0000-0001-5638-3504
Hidewaki NakagawaLaboratory for Cancer Genomics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan. hidewaki@riken.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A germline alteration in the PTEN gene causes a spectrum of disorders conceptualized as PTEN hamartoma tumor syndrome (PHTS), which show high risk of tumor development and a highly variable and complex phenotype. The diagnosis of PHTS is established in a proband by identification of a heterozygous germline PTEN pathogenic variant on molecular genetic testing. In this study, to understand more PTEN-associated clinical phenotype and PHTS in a Japanese population, we extracted 128 germline PTEN rare variants from 113,535 adult Japanese registered in Biobank Japan (BBJ), and categorized 29 pathogenic/likely pathogenic variants in 30 individuals (0.0264%) with ClinVar classifications and ACMG/AMP guideline for PTEN. We examined case-control association in 75,238 patients with various types of cancer and 38,297 non-cancer controls, and identified that PTEN pathogenic variants (PVs) were significantly associated with endometrial cancer (OR = 35.7, P = 9.73E-04) and marginally associated with female breast cancer (OR = 19.5, P = 3.92E-03), especially at young onset and with multiple cancers. We observed that among the 127 disease phenotypes the PTEN PV carriers had uterine fibroid, goiter, ovarian cyst, and epilepsy, which is consistent with PTEN-related phenotypes. We also found that weight/height were significantly higher in adult female carriers with PTEN PV (P = 3.1E-04 and P = 0.0014, respectively), which is consistent with overgrowth syndrome of PHTS. Our results indicate the phenotypical features associated with PTEN PVs in a Japanese population, especially female, and can contribute to the screening for PTEN variants and its associated several phenotypes.

Indexed as

Genetic Predisposition to DiseaseHamartoma Syndrome, MultipleNeoplasmsPTEN PhosphohydrolaseAdultAgedCase-Control StudiesEast Asian PeopleFemaleGerm-Line MutationHumansJapanMaleMiddle AgedPhenotypePTEN PhosphohydrolasePTEN protein, human

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.